Merkel cell carcinoma clinical trials

Seattle Cancer Care Alliance (SCCA) was formed, in part, to bring promising new treatments to patients faster. For Merkel cell carcinoma patients, this means more treatment options at SCCA than you might find elsewhere, including the chance to participate in one of many ongoing clinical trials conducted at SCCA and its partner organizations, Fred Hutch and UW Medicine.

  • Below is a list of Merkel cell carcinoma clinical trials that are currently open and accepting patients at SCCA.
  • For general information about clinical trials, see the Patient Guide to Clinical Trials.

Displaying 4 of 4 trials.

Adjuvant Avelumab in Merkel Cell Cancer (ADAM)
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial of Adjuvant Avelumab (anti-PDL-1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
View Trial
Investigator:
Shailender Bhatia
Study ID:
NCT03271372
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides

A Phase 1 Dose Escalation Trial of Intratumoral Injections of TTI-621 in Subjects with Relapsed and Refractory Percutaneously-Accessible Solid Tumors and Mycosis Fungoides

View Trial
Investigator:
John A. Thompson
Study ID:
NCT02890368
A Study to Investigate the Safety and Efficacy of Nivolumab in Virus-associated Tumors (CheckMate358)

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-963558) In subjects with Virus-Positive and Virus-Negative Tumors

View Trial
Investigator:
Shailender Bhatia
Study ID:
NCT02488759
Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma
Study to Evaluate Cellular Adoptive Immunotherapy Using Polyclonal Autologous CD8+ Antigen-Specific T Cells for Metastatic Merkel Cell Carcinoma in Combination with MHC Class I Up-regulation and the Anti-PD-L1 Antibody Avelumab
View Trial
Investigator:
Aude G. Chapuis
Study ID:
NCT02584829